DIAMEDICA THERAPEUTICS INC (DMAC)
CA25253X2077 - Common Stock
ChartMill assigns a Buy % Consensus number of 84% to DMAC. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 7.14. This target is 186.75% above the current price.
DMAC was analyzed by 9 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about DMAC.
In the previous month the buy percentage consensus was at a similar level.
DMAC was analyzed by 9 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-03-21 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-03-21 | Craig-Hallum | Maintains | Buy -> Buy |
| 2023-06-22 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2022-07-07 | Lake Street | Maintains | Buy |
| 2022-07-07 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2022-07-07 | Craig-Hallum | Maintains | Buy |
| 2021-06-30 | Roth Capital | Maintains | Buy |
| 2021-04-08 | Oppenheimer | Initiate | Outperform |
| 2021-02-17 | Roth Capital | Initiate | Buy |